Vitae Pharmaceuticals (VTAE) to Join NASDAQ Biotechnology Index

Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition will become effective prior to the market open on Monday, December 21, 2015. Vitae is also included in the Russell 3000® and 2000® indices.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information on the NASDAQ Biotechnology Index, visit https://indexes.nasdaqomx.com/.

You May Also Be Interested In

• Crude Inventory Fell 1.7 Million Barrels Last Week - EIA
• Context Therapeutics added to Russell 2000 and Russell 3000 indexes
• Willis Lease Finance added to three Russell 2000 indexes